Notice 11 Aug 2025 business compliance, controlled substances, healthcare, drug enforcement, clinical trials, dea, benuvia operations

💊Benuvia Operations LLC Applies for Controlled Substances Import Registration

Benuvia Operations, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 11 Aug 2025 pharmaceutical industry, controlled substances, import regulations, compliance, drug enforcement

💊Chattem Chemicals Applies for Import of Controlled Substances

Chattem Chemicals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 11 Aug 2025 controlled substances, biopharmaceuticals, compliance, regulation, drug enforcement

💊DEA Notice on Biopharmaceutical Research Company’s Application

Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 8 Aug 2025 compliance, controlled substances, business regulation, drug enforcement, dea, manufacturing

💊Chemtos LLC's Application for Bulk Manufacturing of Controlled Substances

Chemtos, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Rule 8 Aug 2025 business impact, administrative practice and procedure, controlled substances, drug traffic control, drug enforcement, reporting and recordkeeping requirements, regulatory compliance, legal obligations

⚖️Business Implications of Dipentylone as a Controlled Substance

The Drug Enforcement Administration (DEA) is establishing a specific listing and DEA Controlled Substances Code Number (drug code) for 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one (dipentylone; N,N-dimethylpentylone) in schedule I of the Controlled Substances Act (CSA). Although dipentylone is not specifically listed in schedule I of the CSA with its own unique drug code, it is a schedule I controlled substances in the United States because it is a positional isomer of N-ethylpenthylone (controlled August 31, 2018), which is a schedule I hallucinogen. Therefore, DEA is simply amending the schedule I hallucinogenic substances list in its regulations to separately include dipentylone.

Learn More
Notice 25 Jul 2025 compliance, healthcare, dea, florida, drug enforcement, medical regulation

🚫DEA Revokes Registration of Dr. Taha Dias for Prescription Violations

The Drug Enforcement Administration issued a decision to revoke the DEA Certificate of Registration for Dr. Taha Dias, citing repeated violations of federal and Florida state law related to the improper issuance of prescriptions for controlled substances without legitimate medical purpose, jeopardizing public safety and regulatory compliance.

Learn More
Proposed Rule 25 Jul 2025 compliance, regulatory, administrative practice and procedure, reporting and recordkeeping requirements, business impact, controlled substances, drug traffic control, drug enforcement, benzodiazepines

⚖️Proposed Rule for Scheduling Designer Benzodiazepines as Controlled Substances

The Drug Enforcement Administration proposes placing clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, as identified in this proposed rule, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action will also enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.

Learn More
Notice 25 Jul 2025 compliance, information collection, law enforcement, public comments, drug enforcement

📝DEA Notice on User Access Request Form for EPIC System Portal

The Drug Enforcement Administration, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

Learn More
Notice 22 Jul 2025 compliance, healthcare, utah, drug enforcement, regulatory action, physician licensing

🚫DEA Revocation of Dr. Thomas Draschil's Registration - Impacts for Business

The Drug Enforcement Administration issued an Order to Show Cause to Thomas Draschil, M.D., proposing the revocation of his DEA registration due to his lack of authority to handle controlled substances in Utah. The agency highlights the importance of maintaining state licensing to dispense controlled substances, emphasizing regulatory compliance requirements for practitioners.

Learn More
Notice 17 Jul 2025 compliance, import regulations, pharmaceutical, controlled substances, justice department, drug enforcement, cerilliant corporation

⚖️Cerilliant Corporation's Application for Import of Controlled Substances

Cerilliant Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More